Abstract:Although the robust antidepressant effects of the N -methyl- d -aspartate receptor (NMDAR) antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the precise molecular and cellular mechanisms underlying its antidepressant effects remain unknown. NMDAR inhibition and the subsequent α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) activation are suggested to play a role in the antidepressant effects of ketamine. Although ( R )-ketamine is a less potent NMDAR antagonist than ( S )-ketamine, ( R )-ketamine has shown more marked and longer-lasting antidepressant-like effects than ( S )-ketamine in several animal models of depression. Furthermore, non-ketamine NMDAR antagonists do not exhibit robust ketamine-like antidepressant effects in patients with depression. These findings suggest that mechanisms other than NMDAR inhibition play a key role in the antidepressant effects of ketamine. Duman’s group demonstrated that the activation of mammalian target of rapamycin complex 1 (mTORC1) in the medial prefrontal cortex is reportedly involved in the antidepressant effects of ketamine. However, we reported that mTORC1 serves a role in the antidepressant effects of ( S )-ketamine, but not of ( R )-ketamine, and that extracellular signal-regulated kinase possibly underlie the antidepressant effects of ( R )-ketamine. Several lines of evidence have demonstrated that brain-derived neurotrophic factor (BDNF) and its receptor, tyrosine kinase receptor B (TrkB), are crucial in the antidepressant effects of ketamine and its two enantiomers, ( R )-ketamine and ( S )-ketamine, in rodents. In addition, (2 R ,6 R )-hydroxynormetamine [a metabolite of ( R )-ketamine] and ( S )-norketamine [a metabolite of ( S )-ketamine] have been shown to exhibit antidepressant-like effects on rodents through the BDNF–TrkB cascade. In this review, we discuss recent findings on the molecular and cellular mechanisms underlying the antidepressant effects of enantiomers of ketamine and its metabolites. It may be time to reconsider the hypothesis of NMDAR inhibition and the subsequent AMPAR activation in the antidepressant effects of ketamine.

Translational control by ketamine and its implications for comorbid cognitive deficits in depressive disorders

Ketamine Exerts Its Sustained Antidepressant Effects Via Cell-Type-specific Regulation of Kcnq2.

Ketamine reverses chronic corticosterone-induced behavioral deficits and hippocampal synaptic dysfunction by regulating eIF4E/BDNF signaling

Differentially regulated targets in the fast-acting antidepressant effect of (R)-ketamine: A systems biology approach

Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism

Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions

A molecular perspective on mGluR5 regulation in the antidepressant effect of ketamine

Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E

Molecular and Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine Enantiomers and Its Metabolites

A Multiscale View of the Mechanisms Underlying Ketamine’s Antidepressant Effects: An Update on Neuronal Calcium Signaling

Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers

Is the antidepressant effect of ketamine separate from its psychotomimetic effect? A review of rodent models

Uncovering the Underlying Mechanisms of Ketamine As a Novel Antidepressant

Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine

Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration

Effects of ketamine on GABAergic and glutamatergic activity in the mPFC: biphasic recruitment of GABA function in antidepressant-like responses

Serotonergic transmission plays differentiated roles in the rapid and sustained antidepressant-like effects of ketamine

The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality

NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research

Ketamine-induced Antidepressant Effects Are Associated with AMPA Receptors-Mediated Upregulation of Mtor and BDNF in Rat Hippocampus and Prefrontal Cortex.